Methods of modulating fibrosis

Details Methods of modulating fibrosis Methods of modulating fibrosis

2007-02-13

2007-02-13

Landsman, Robert S. (Department: 1647)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S141100, C424S143100, C424S145100

Reexamination Certificate

active

09907045

ABSTRACT:
The invention features methods of modulating fibrosis and/or angiogenesis by inhibiting components of the VEGF signaling pathway. The methods are useful in the treatment of fibrotic and or angiogenesis related disorders.

REFERENCES:
patent: 6001622 (1999-12-01), Dedhar et al.
patent: 6100090 (2000-08-01), Monia et al.
patent: 6410322 (2002-06-01), Robinson
patent: 6455283 (2002-09-01), Ferrara et al.
patent: 6620784 (2003-09-01), Ferrara et al.
patent: 6734285 (2004-05-01), Hu et al.
patent: WO 94/10202 (1994-05-01), None
patent: WO 97/34920 (1997-09-01), None
patent: WO 00/13706 (2000-03-01), None
Jiang et al., “Phosphatidylinositol 3-Kinase signaling mediates . . . ”, Feb. 2000, Proc.Natl.Acad.Sci., vol. 97, No. 4;1749-1753.
Oikawa et al., “Potent inhibition of angiogenesis by wortmannin . . . ”, 1996, Eur.J.Pharmacol, vol. 318;93-96.
Snyder et al., “Effects of inhibitors of phosphatidylinositol 3-OH kinase . . . ”, 1998, abstract, Blood, vol. 92, No. 10, Pt. 1, Suppl. 1;426a-427a.
Abraham et al. (2000)J. Biol. Chem.275, 15220.
Aiello et al. (1998)Diabetes Care21, 143.
Boes et al. (1999)Endocrinology140, 1575.
Chen et al., Oct. (2000)J Mol Cell Cardiol.32(10):1805-19.
Clarkson et al. Sep. (1999)Curr Opin Nephrol Hypertens.8(5):543-8. Review. No abstract available.
Dammeier et al. (1998)J. Biol. Chem.273, 18185-18190.
Dammeier et al. Aug. (1998)Int J Biochem Cell Biol.30(8):909-22.
Firestein (1999)J. Clin. Invest.103, 3-4.
Frazier et al. (1996)J. Invest. Dermatol.107, 404.
Haustein et al. Jul (1998)J Eur Acad Dermatol Venereol.11(1):1-8. Review.
Holmes et al. Apr. (2001)J Biol Chem.276(14):10594-601.
Igarashi et al. (1996)J. Invest. Dermatol.106, 729-733.
Ito et al. Mar (2001)J Am Soc Nephrol.12(3):472-84.
Kireeva et al. (1997)Exp. Cell Res.233, 63.
Klagsbrun & D'Amore, (1991)Annu. Rev. Physiol.53, 217.
Lopez et al. (1996)Invest. Ophthalmol.&Visual Sci.37, 855.
Mola et al. Jul (1999)Ann. Surg.230(1):63-71.
Mori et al. Oct (1999) J Cell Physiol.181(1):153-9.
Murphy et al. (1999)J. Biol. Chem.274, 5830-5834.
Pendurthi et al. (2000)J. Biol. Chem.275, 14632-14641.
Petrova et al. (1999)Exp. Cell Res.253, 117-130.
Ricupero et al. (2000)J. Biol. Chem.275, 12475-12480.
Sato et al. Jan (2000)J Rheumatol.27(1):149-54.
Lasky et al., “Connective tissue growth factor mRNA expression . . . ”, 1998, Amer. Physiol. Soc., p. L365-371.
King, “Cell biology as an approach to the study of the vascular complications of diabetes,”Metabolism, 34(12 Suppl. 1):17-22, Abstract only (1985).
King et al., “Regulation of vascular Permeability in Cell Culture,”Diabetes, 36:1460-1467 (1987).
Rauniyar et al., “Differential Effects of Bactericidal/Permeability-Increasing Protein (BPI) Analogues on Retinal Neovascularization and Retinal Pericyte Growth,”Invest. Ophthalmol. Vis. Sci., 43(2):503-509 (2002).
Suzuma et al., “Vascular Endothelial Growth Factor Induces Expression of Connective Tissue Growth Factor via FDR, Flt1, and Phosphatidylinositol 3-Kinase-Akt-dependent Pathways in Retinal Vascular Cells,”J. Biol Chem., 275(52):40725-40731 (2000).
Takagi et al., “Adenosine Mediates Hypoxic Induction of Vascular Endothelial Growth Factor in Retinal Pericytes and Endothelial Cells,”Invest. Ophthalmol. Vis. Sci., 37(11):2165-2176 (1996).
Takagi et al., “Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes,”Diabetes, 45(8):1016-1023, Abstract only (1996).
Kim et al., “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growthin vivo,” Nature, 362:841-844 (1993).
Hamada et al., “Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice.” J. Immunol. 175(2):1224-1231 (2005).
Kalluri and Sukhatme, “Fibrosis and angiogenesis.” Curr. Opin. Nephrol. Hypertens. 9(4):413-8 (2000).
Medford et al., “VEGF in idiopathic ILD.” Thorax 60(4):353 (2005).
Richter et al., “VEGF levels in pulmonary fibrosis.” Thorax 60(2):171 (2005).
Rojkind and Greenwel, “Animal models of liver fibrosis.” inAnimal Models in Liver Research, (Cornelius, Ed.), Adv. Vet. Sci. Comp. Med. (37):333-355 (1993).
Saleem et al., “Author's Reply.” Thorax 60(4):353-354 (2005).
Simler et al., “Angiogenic cytokines in patients with idiopathic interstitial pneumonia.” Thorax 59:581-585 (2004).
Yoshiji et al., “Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis.” Gut 52:1347-1354 (2003).
Babic et al., “Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion . . . ” Mol. and Cell. Biol. 19:2958-2966, 1999.
Suzuma et al., “Vascular endothelial growth factor induces expression of connective tissue growth . . . ” J. of Biol. Chem. 275:40725-40731, 2000.
Wunderlich et al., “Regulation of connective tissue growth factor gene expression in retinal vascular endothelial . . . ” Graefe's Archive for Clinical & Exp. Ophthalmology 238:910-915, 2000.

Affiliated with

Also associated with

Rating

Methods of modulating fibrosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of modulating fibrosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of modulating fibrosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3867082